26 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
n (%) 1 ( 14.3) 0 0 0 0 1 (3.7) Ethnicity Hispanic/Latino n (%) 2 (28.6) 0 0 0 0 2 (7.4) Not Hispanic/Latino n (%) 5 (71.4) 6 (100.0) 7 (100.0) 7 … (50.0%) 5 (55.6%) 7 (53.8%) White 4 (100.0%) 8 (88.9%) 12 (92.3%) Other 0 1 (11.1%) 1 (7.7%) Not Hispanic or Latino 3 (75.0%) 8 (88.9%) 11 (84.6
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
) 24 (88.9) Asian n (%) 0 0 1 ( 14.3) 1 ( 14.3) 2 ( 10.0) 2 ( 7.4) American Indian n (%) 1 ( 14.3) 0 0 0 0 1 (3.7) Ethnicity Hispanic/Latino n (%) 2 … (28.6) 0 0 0 0 2 (7.4) Not Hispanic/Latino n (%) 5 (71.4) 6 (100.0) 7 (100.0) 7 (100.0) 20 (100.0) 25 (92.6) SD: Standard deviation
MAD Trial Patient
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
14 Aug 23
Other Events
8:00am
( 85.7) 18 ( 90.0) 24 (88.9) Asian n (%) 0 0 1 ( 14.3) 1 ( 14.3) 2 ( 10.0) 2 ( 7.4) American Indian n (%) 1 ( 14.3) 0 0 0 0 1 (3.7) Ethnicity Hispanic … /Latino n (%) 2 (28.6) 0 0 0 0 2 (7.4) Not Hispanic/Latino n (%) 5 (71.4) 6 (100.0) 7 (100.0) 7 (100.0) 20 (100.0) 25 (92.6) SD: Standard deviation
MAD
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
15 May 23
Results of Operations and Financial Condition
7:05am
(100.0%) 8 (88.9%) 12 (92.3%) Other 0 1 (11.1%) 1 (7.7%) Not Hispanic or Latino 3 (75.0%) 8 (88.9%) 11 (84.6%) Hispanic or Latino 1 (25.0%) 1 (11.1
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
11 May 21
Other Events
8:34am
1 ( 14.3) 1 ( 14.3) 2 ( 10.0) 2 ( 7.4) American Indian n (%) 1 ( 14.3) 0 0 0 0 1 (3.7) Ethnicity Hispanic/Latino n (%) 2 (28.6) 0 0 0 0 2 (7.4 … ) Not Hispanic/Latino n (%) 5 (71.4) 6 (100.0) 7 (100.0) 7 (100.0) 20 (100.0) 25 (92.6) SD: Standard deviation
MAD Trial Patient Disease Characteristics
8-K
EX-99.1
ator9x3
8 Dec 20
Regulation FD Disclosure
7:40am
8-K
EX-99.1
5dflnt88
1 Jul 21
Other Events
6:11am
8-K
EX-99.1
kftq7m
14 Jun 21
Other Events
5:21pm
8-K
EX-99.1
pchmmtc796ssb4kl8s
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
8-K
EX-99.2
nc2j 720hwseum
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.2
xdjtx2d1cl02 03fe
14 Sep 22
Other Events
7:05am
8-K
EX-99.2
pni7c0v2vjj0
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am
8-K
EX-99.2
050zfu
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am
8-K
EX-99.2
s8sro 0zmn
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
8-K
EX-99.2
o8p8wiuj
12 Nov 21
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
7:21am
8-K
EX-99.1
qi4wt
28 Feb 22
Results of Operations and Financial Condition
8:16am
8-K
EX-99.2
ncn87jwb
12 Aug 21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10:29am
8-K
EX-99.1
tu24lf
18 May 21
Other Events
3:09pm
8-K
EX-99.2
n3ffg qme7n2
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
8-K
EX-99.2
b8lemq7pgvaofu2bl
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am